Personality trait dimensions and the pharmacological treatment of borderline personality disorder

Erika F. H. Saunders, Kenneth R. Silk

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The number of well-designed placebo-controlled studies on pharmacological treatment of borderline personality disorder has been small. We present a breakdown of results of placebo-controlled pharmacological studies, sorting target symptoms into the trait dimensions of affective instability, anxiety inhibition, cognitive-perceptual disturbances, and impulsivity-aggression. Twenty randomized placebo-controlled pharmacological trials studying typical and atypical antipsychotics, selective serotonin reuptake and monoamine oxidase inhibitors, tricyclic antidepressants, mood stabilizers, and benzodiazepines were included. A relative measure of the weight of an outcome was determined by (1) dividing the number of positive comparisons for a drug class by the total number of comparisons of all drugs of all classes for each dimension and (2) dividing the number of positive comparisons for a drug class by the total number of comparisons for that particular drug class for that trait dimension. Antipsychotics (neuroleptics and atypicals) had the most evidence for each of the traits with both methods. Our results are compared with the results of 2 meta-analyses, 1 guideline set, and 1 other systematic review. We found little concordance across these studies. We propose a consortium to discuss guidelines for future studies, including agreement as to what should be measured to determine the outcome and adoption of standardized instruments to measure that outcome.

Original languageEnglish (US)
Pages (from-to)461-467
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume29
Issue number5
DOIs
StatePublished - Oct 1 2009

Fingerprint

Borderline Personality Disorder
Personality
Pharmacology
Antipsychotic Agents
Placebos
Pharmaceutical Preparations
Outcome Assessment (Health Care)
Guidelines
Monoamine Oxidase Inhibitors
Impulsive Behavior
Tricyclic Antidepressive Agents
Therapeutics
Aggression
Benzodiazepines
Meta-Analysis
Serotonin
Anxiety
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

@article{85f180efaff7481ea686c5c63502f1ff,
title = "Personality trait dimensions and the pharmacological treatment of borderline personality disorder",
abstract = "The number of well-designed placebo-controlled studies on pharmacological treatment of borderline personality disorder has been small. We present a breakdown of results of placebo-controlled pharmacological studies, sorting target symptoms into the trait dimensions of affective instability, anxiety inhibition, cognitive-perceptual disturbances, and impulsivity-aggression. Twenty randomized placebo-controlled pharmacological trials studying typical and atypical antipsychotics, selective serotonin reuptake and monoamine oxidase inhibitors, tricyclic antidepressants, mood stabilizers, and benzodiazepines were included. A relative measure of the weight of an outcome was determined by (1) dividing the number of positive comparisons for a drug class by the total number of comparisons of all drugs of all classes for each dimension and (2) dividing the number of positive comparisons for a drug class by the total number of comparisons for that particular drug class for that trait dimension. Antipsychotics (neuroleptics and atypicals) had the most evidence for each of the traits with both methods. Our results are compared with the results of 2 meta-analyses, 1 guideline set, and 1 other systematic review. We found little concordance across these studies. We propose a consortium to discuss guidelines for future studies, including agreement as to what should be measured to determine the outcome and adoption of standardized instruments to measure that outcome.",
author = "Saunders, {Erika F. H.} and Silk, {Kenneth R.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1097/JCP.0b013e3181b2b9f3",
language = "English (US)",
volume = "29",
pages = "461--467",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Personality trait dimensions and the pharmacological treatment of borderline personality disorder. / Saunders, Erika F. H.; Silk, Kenneth R.

In: Journal of Clinical Psychopharmacology, Vol. 29, No. 5, 01.10.2009, p. 461-467.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Personality trait dimensions and the pharmacological treatment of borderline personality disorder

AU - Saunders, Erika F. H.

AU - Silk, Kenneth R.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - The number of well-designed placebo-controlled studies on pharmacological treatment of borderline personality disorder has been small. We present a breakdown of results of placebo-controlled pharmacological studies, sorting target symptoms into the trait dimensions of affective instability, anxiety inhibition, cognitive-perceptual disturbances, and impulsivity-aggression. Twenty randomized placebo-controlled pharmacological trials studying typical and atypical antipsychotics, selective serotonin reuptake and monoamine oxidase inhibitors, tricyclic antidepressants, mood stabilizers, and benzodiazepines were included. A relative measure of the weight of an outcome was determined by (1) dividing the number of positive comparisons for a drug class by the total number of comparisons of all drugs of all classes for each dimension and (2) dividing the number of positive comparisons for a drug class by the total number of comparisons for that particular drug class for that trait dimension. Antipsychotics (neuroleptics and atypicals) had the most evidence for each of the traits with both methods. Our results are compared with the results of 2 meta-analyses, 1 guideline set, and 1 other systematic review. We found little concordance across these studies. We propose a consortium to discuss guidelines for future studies, including agreement as to what should be measured to determine the outcome and adoption of standardized instruments to measure that outcome.

AB - The number of well-designed placebo-controlled studies on pharmacological treatment of borderline personality disorder has been small. We present a breakdown of results of placebo-controlled pharmacological studies, sorting target symptoms into the trait dimensions of affective instability, anxiety inhibition, cognitive-perceptual disturbances, and impulsivity-aggression. Twenty randomized placebo-controlled pharmacological trials studying typical and atypical antipsychotics, selective serotonin reuptake and monoamine oxidase inhibitors, tricyclic antidepressants, mood stabilizers, and benzodiazepines were included. A relative measure of the weight of an outcome was determined by (1) dividing the number of positive comparisons for a drug class by the total number of comparisons of all drugs of all classes for each dimension and (2) dividing the number of positive comparisons for a drug class by the total number of comparisons for that particular drug class for that trait dimension. Antipsychotics (neuroleptics and atypicals) had the most evidence for each of the traits with both methods. Our results are compared with the results of 2 meta-analyses, 1 guideline set, and 1 other systematic review. We found little concordance across these studies. We propose a consortium to discuss guidelines for future studies, including agreement as to what should be measured to determine the outcome and adoption of standardized instruments to measure that outcome.

UR - http://www.scopus.com/inward/record.url?scp=70349659169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349659169&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3181b2b9f3

DO - 10.1097/JCP.0b013e3181b2b9f3

M3 - Article

VL - 29

SP - 461

EP - 467

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -